Myriad Genetics (MYGN) AI Stock Analysis

• Market Cap: $592.69M
• Dividend Yield: N/A
• Average Volume (3M): 2.03M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.79
• Revenue Growth: 3.83%
• EPS Growth: -137.31%
• Country: US
• Employees: 2,700
• Sector: Healthcare
• Sector Strength: 51
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.05
• Shares Outstanding: 93,044,624
• 10 Day Avg. Volume: 1,260,760
• 30 Day Avg. Volume: 2,033,616
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.96
• Enterprise Value/Revenue: 0.69
• Enterprise Value/Gross Profit: 0.97
• Enterprise Value/Ebitda: -1.61
• 1Y Price Target: $7.50
• Price Target Upside: 8.70% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7

• Rating: 52 Neutral
• Price Target: $6.00 ▼(-13.04% Downside)

Myriad Genetics' overall stock score reflects strong revenue growth and positive earnings call sentiment. However, significant challenges in profitability, cash flow management, and valuation weigh heavily on the score. The technical analysis shows short-term strength, but longer-term indicators suggest caution.

Positive Factors

Financial Performance

The adjusted EBITDA guidance has been increased, suggesting improved financial expectations.

Revenue Guidance

The company raised its revenue guidance by $8 million, indicating a potential rebound in performance.

Negative Factors

Competitive Pressures

Intensifying competitive pressures in NIPT and in hereditary cancer testing are limiting growth potential longer term.

Revenue Challenges

Management has lowered the revenue guidance by $35 million to reflect ongoing challenges, indicating uncertainty in achieving future targets.

Stock Performance

The reduced price target from $15 to $7 indicates lowered expectations for the company's performance.

Myriad Genetics Business Overview & Revenue Model

Company Description

Myriad Genetics, Inc. is a molecular diagnostics company based in the United States that focuses on developing and commercializing innovative genetic tests. The company operates in the healthcare sector and specializes in precision medicine, primarily through its offerings in hereditary cancer testing, autoimmune disease testing, and pharmacogenomics. Myriad's core products include tests that assess the risk of cancer and help tailor treatment options based on genetic information, providing crucial insights for patients and healthcare providers.

How the Company Makes Money

Myriad Genetics generates revenue primarily through the sale of its genetic testing services. The company operates a fee-for-service model, where healthcare providers order tests for patients, and Myriad bills the insurers or patients directly. Key revenue streams include the hereditary cancer testing segment, which assesses genetic mutations in patients to evaluate their cancer risk, and the myRisk test that evaluates multiple cancer types simultaneously. Additionally, Myriad earns income from its pharmacogenomic tests that help determine how patients metabolize certain medications, enhancing treatment efficacy. The company has also established significant partnerships with various healthcare organizations and payers, which facilitates broader access to its tests and enhances its market presence. Factors contributing to earnings include increasing awareness and demand for genetic testing, advancements in technology, and the growing emphasis on personalized medicine.

Myriad Genetics Financial Statement Overview

Summary

Myriad Genetics faces significant challenges with declining revenues and persistent losses impacting profitability and cash flow. While the balance sheet remains relatively stable with a strong equity position, the company must address operational inefficiencies and work towards sustainable revenue growth to enhance financial performance.

Income Statement

The income statement shows a decline in revenue from $837.6M to $831.3M in TTM, indicating a negative revenue growth. The gross profit margin remains relatively stable with slight fluctuations, while net income remains negative, impacting net profit margins significantly. The company is experiencing negative EBIT and EBITDA margins, suggesting ongoing operational challenges.

Balance Sheet

The balance sheet reflects a moderate debt-to-equity ratio, with total debt increasing slightly but still manageable. The equity ratio is strong, indicating a solid asset base supported by equity. However, the return on equity is negative due to consistent net losses, signaling inefficiencies in generating shareholder value.

Cash Flow

Cash flow analysis reveals a negative operating cash flow, which has improved slightly in TTM. Free cash flow remains negative, indicating challenges in funding operations without external financing. The operating cash flow to net income ratio is negative, highlighting issues in converting income into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	832.90M	837.60M	753.20M	678.40M	690.60M	557.00M
Gross Profit	586.70M	585.40M	517.00M	476.40M	493.00M	378.80M
EBITDA	-355.00M	-59.50M	-186.10M	-67.80M	14.10M	-123.40M
Net Income	-395.20M	-127.30M	-263.30M	-112.00M	-27.20M	-223.70M
Balance Sheet
Total Assets	677.30M	1.03B	1.15B	1.20B	1.32B	1.42B
Cash, Cash Equivalents and Short-Term Investments	74.40M	102.40M	140.90M	114.90M	339.80M	150.70M
Total Debt	154.60M	140.30M	152.10M	145.00M	92.30M	0.00
Total Liabilities	289.20M	326.50M	363.30M	312.90M	352.90M	537.80M
Stockholders Equity	388.10M	701.10M	783.20M	885.80M	967.80M	881.00M
Cash Flow
Free Cash Flow	-50.00M	-38.40M	-184.20M	-151.60M	600.00K	-40.10M
Operating Cash Flow	-22.60M	-8.70M	-110.90M	-106.30M	18.60M	-26.90M
Investing Cash Flow	-13.60M	-11.90M	31.90M	-77.50M	274.40M	61.60M
Financing Cash Flow	15.20M	-7.40M	152.90M	-8.00M	-150.60M	-1.00M

Myriad Genetics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.90
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MYGN, the sentiment is Positive. The current price of 6.9 is above the 20-day moving average (MA) of 5.87, above the 50-day MA of 5.28, and below the 200-day MA of 9.14, indicating a neutral trend. The MACD of 0.36 indicates Negative momentum. The RSI at 72.03 is Negative, neither overbought nor oversold. The STOCH value of 91.86 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MYGN.

Myriad Genetics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FLGT	63 Neutral	$678.60M	―	-4.54%	―	4.31%	69.57%
CSTL	59 Neutral	$696.49M	30.59	-2.15%	―	20.40%	-165.41%
GRAL	59 Neutral	$1.18B	―	-17.68%	―	22.37%	86.08%
CDNA	56 Neutral	$727.08M	13.56	20.73%	―	14.72%	―
MYGN	52 Neutral	$592.69M	―	-70.03%	―	3.83%	-137.31%
Sector *	51 Neutral	$7.86B	-0.33	-41.57%	2.23%	23.26%	-2.03%
NEO	48 Neutral	$1.13B	―	-11.76%	―	9.70%	-30.94%

Myriad Genetics Corporate Events

Myriad Genetics Appoints Ben R. Wheeler as CFO

On August 18, 2025, Myriad Genetics announced the appointment of Ben R. Wheeler as the new Chief Financial Officer, effective August 16, 2025, following the departure of Scott J. Leffler from the role. Wheeler, who has been with the company for over 13 years, brings extensive financial expertise and leadership experience, which is expected to support Myriad’s growth strategy. The company also reaffirmed its financial guidance for the full year 2025, indicating confidence in its strategic direction.

Myriad Genetics Secures $200 Million Credit Agreement

On July 31, 2025, Myriad Genetics entered into a $200 million credit agreement with OrbiMed Royalty & Credit Opportunities IV, LP, which includes a $125 million initial loan and an option for an additional $75 million until June 30, 2027. This credit facility, secured by Myriad’s assets, will support the company’s working capital needs and growth strategy, replacing its previous ABL facility.